Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.

Archive ouverte

Lanternier, Fanny | Cohen-Akenine, Annick | Palmerini, Fabienne | Feger, Frédéric | Yang, Ying | Zermati, Yael | Barète, Stéphane | Sans, Beatrix | Baude, Cédric | Ghez, David | Suarez, Felipe | Delarue, Richard | Casassus, Philippe | Bodemer, Christine | Catteau, Adeline | Soppelsa, Frédérique | Hanssens, Katia | Arock, Michel | Sobol, Hagay | Fraitag, Sylvie | Canioni, Danièle | Moussy, Alain | Launay, Jean Marie | Dubreuil, Patrice | Hermine, Olivier | Lortholary, Olivier

Edité par CCSD ; Public Library of Science -

International audience. Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease started during childhood (Group 1, n = 28) with those of patients whose disease started at adult's age (Group 2, n = 114). Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42% and 77% of patients in groups 1 and 2, respectively (p<0.001). 816 c-kit mutation was associated with systemic mastocytosis in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p = 0.0001). Other c-kit activating mutations were found in 23% of patients with mastocytosis' onset before the age of 5, 0% between 6 and 15 years and 2% at adults' age (p<0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the age of disease's onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy.

Suggestions

Du même auteur

Case-control cohort study of patients' perceptions of disability in mastocytosis.

Archive ouverte | Hermine, Olivier | CCSD

BACKGROUND: Indolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-c...

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

Archive ouverte | Gabillot-Carré, Marion | CCSD

International audience. Two classes of oncogenic mutations of the c-kit tyrosine kinase have been described: the juxtamembrane domain V560G mutation, which is preferentially found in gastrointestinal stromal tumors ...

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

Archive ouverte | Lortholary, Olivier | CCSD

International audience. BACKGROUND:Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits K...

Chargement des enrichissements...